2seventy bio Q2 2024 Adj. EPS $(0.29) Beats $(0.65) Estimate, Sales $8.967M Miss $14.195M Estimate
Portfolio Pulse from Benzinga Newsdesk
2seventy bio (NASDAQ:TSVT) reported Q2 2024 adjusted EPS of $(0.29), beating the estimate of $(0.65). However, sales of $8.967M missed the $14.195M estimate and were down 75.12% from the same period last year.

August 07, 2024 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
2seventy bio reported better-than-expected Q2 2024 EPS of $(0.29) but missed sales estimates with $8.967M, a 75.12% decrease YoY.
The better-than-expected EPS is a positive sign, but the significant miss on sales and the large YoY decline in revenue are concerning. This mixed result is likely to create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100